Jefferies Financial Group Upgrades Pediatrix Medical Group (NYSE:MD) to “Strong-Buy”

Pediatrix Medical Group (NYSE:MD) was upgraded by equities research analysts at Jefferies Financial Group to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Several other analysts have also recently weighed in on the stock. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a research note on Monday, December 29th. UBS Group reduced their price target on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 24th. Zacks Research cut Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft set a $19.00 price objective on Pediatrix Medical Group in a research report on Friday, February 20th. Finally, Truist Financial cut their target price on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating for the company in a research note on Thursday, February 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $19.80.

Pediatrix Medical Group Stock Down 1.9%

NYSE MD opened at $19.42 on Thursday. The business’s fifty day simple moving average is $20.97 and its 200-day simple moving average is $19.99. The company has a quick ratio of 1.66, a current ratio of 1.66 and a debt-to-equity ratio of 0.66. The firm has a market cap of $1.61 billion, a PE ratio of 10.01 and a beta of 0.79. Pediatrix Medical Group has a 52 week low of $11.84 and a 52 week high of $24.99.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings data on Thursday, February 19th. The company reported $0.50 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.53 by ($0.03). Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The firm had revenue of $493.77 million during the quarter, compared to analysts’ expectations of $486.23 million. During the same period in the prior year, the company posted $0.51 EPS. The company’s revenue for the quarter was down 1.7% compared to the same quarter last year. As a group, equities analysts anticipate that Pediatrix Medical Group will post 1.38 earnings per share for the current year.

Insider Activity

In other news, CEO Mark S. Ordan sold 23,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $22.41, for a total value of $515,430.00. Following the sale, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at approximately $6,785,860.05. The trade was a 7.06% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.90% of the company’s stock.

Institutional Trading of Pediatrix Medical Group

Several institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its position in Pediatrix Medical Group by 23.8% in the first quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock valued at $320,000 after purchasing an additional 4,247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Pediatrix Medical Group by 4.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company’s stock worth $743,000 after buying an additional 2,251 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Pediatrix Medical Group by 4.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company’s stock valued at $3,891,000 after buying an additional 12,171 shares in the last quarter. Atria Investments Inc grew its stake in shares of Pediatrix Medical Group by 9.4% in the second quarter. Atria Investments Inc now owns 16,435 shares of the company’s stock valued at $236,000 after buying an additional 1,411 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Pediatrix Medical Group by 284.6% in the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 175,987 shares of the company’s stock valued at $2,525,000 after buying an additional 130,226 shares during the period. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.